Guest blog: Patents in the biopesticide industry revealed

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Guest blog: Patents in the biopesticide industry revealed

Who is applying for patents in the biopesticide industry? Rubal Walia of INDUS TechInnovations explains

Although synthetic chemical fertilizers occupy a large share of pesticide market, biopesticides are gradually gaining significance. We have been looking at the patent landscape as well as the trends and patterns emerging in the Biopesticide industry.

We studied the patent filings in this technology area to understand the investments and patenting efforts being made. The infographic below outlines some interesting trends such as the pace of progress over the last decade, the geographical distribution of patents, patent transactions between different organisations and top patent asset holders.

The report displays a steady increase in published patents over the years, with 2012 revealing a sharp rise. Geographically, the US and China have dominated this area in patents and applications, followed by Europe. In addition, Monsanto, one of the pioneers in developing genetically modified seeds, leads the race as the top patent asset holder, with more than 1,400 patents. Pioneer, a Dupont company, is close behind with more than 1,000 patents.

The report also indicates that Monsanto is among the top acquirers of patents, buying patents from companies such as D&PL Technologies, Pharmacia, and Ecogen. Rivals Bayer and Gibraltar Business Capital have also acquired a large number of patents. You can see more information in the graphic.

Image The infographic was produced by Relecura, a patent and portfolio analysis platform developed by INDUS TechInnovations.

more from across site and SHARED ros bottom lb

More from across our site

AIPPI has pulled the plug on its planned 2027 World Congress, and INTA has seemingly committed to hosting a meeting there, but the concerns won’t abate
Despite being outspent by a wealthy opponent, a trial attorney at King & Spalding says ‘relentless pursuit of the truth’ helped his team secure a $420m damages award for mobile gaming client
190 drugs face loss of exclusivity between 2026 and 2030, with the list including Bristol Myers Squibb’s blood-thinning drug Eliquis and immunotherapy medication Opdivo
Nokia, represented by a team from Bird & Bird, adjudged to have made fair offer to Asus and Acer in UK SEP dispute
Azhar Sadique and Kane Ridley, who founded the London office in 2023, are now both working in legal tech and AI-related roles, while another UK-based lawyer has also left
Partner Pierre Pérot rejoins the firm he left in 2022 alongside another returning lawyer, associate Camille Abba
Vaping dispute, in which Stobbs and Brandsmiths are the representatives, tested how the UK's Human Rights Act can apply to injunctions restraining unjustified threats
An AI platform being sold for £40m, and lateral hires involving law firms Womble Bond Dickinson and Cadwell Thomas were among the top talking points
With the London Annual Meeting behind us, we look back at some of the lessons learned this week and ahead to what 2027 will bring
In-house counsel aren’t impressed with law firms’ international networks, but practitioners say they are crucial for business
Gift this article